爪真菌症(爪白癬):治療薬開発パイプライン分析

【英語タイトル】Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2018

Global Markets Directが出版した調査資料(GMDHC10088IDB)・商品コード:GMDHC10088IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2018年1月18日
・ページ数:68
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥218,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥654,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における爪真菌症(爪白癬)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・爪真菌症(爪白癬)の概要
・爪真菌症(爪白癬)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・爪真菌症(爪白癬)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・爪真菌症(爪白癬)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・爪真菌症(爪白癬)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2018

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2018, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 2, 6, 4, 2 and 2 respectively.

Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) – Overview
Onychomycosis (Tinea Unguium) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Onychomycosis (Tinea Unguium) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Onychomycosis (Tinea Unguium) – Companies Involved in Therapeutics Development
Almirall SA
Blueberry Therapeutics Ltd
Dermala Inc
Eisai Co Ltd
Helix BioMedix Inc
Hexima Ltd
Kaken Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Moberg Pharma AB
NAL Pharmaceuticals Ltd
Novabiotics Ltd
Novan Inc
Viamet Pharmaceuticals Inc
Onychomycosis (Tinea Unguium) – Drug Profiles
BB-0305 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Onychomycosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Onychomycosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ELS-160 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosravuconazole – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-1275 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HXP-124 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KP-607 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ME-1111 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3210 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitric oxide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-213 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-3058 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
terbinafine hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VT-1161 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Onychomycosis (Tinea Unguium) – Dormant Projects
Onychomycosis (Tinea Unguium) – Discontinued Products
Onychomycosis (Tinea Unguium) – Product Development Milestones
Featured News & Press Releases
Jan 11, 2018: Novan to Present Positive Phase 2 Results for SB208 Antifungal Program at Winter Clinical Dermatology Conference
Nov 21, 2017: Hexima Receives Approval to Conduct a Phase 1/2a Study for Fungal Nail Infections
Nov 20, 2017: Moberg Pharma replaces CRO in Phase 3 studies for MOB-015
Nov 08, 2017: Moberg Pharma provides update on timeline for MOB-015
Jul 27, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the American Podiatric Medical Association Annual Meeting
Jun 21, 2017: Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the 4th International Summit on Nail Diseases
Apr 12, 2017: Novan Reports Positive Topline Results with SB208 in Phase 2 Trial
Mar 06, 2017: Viamet Presents Positive Results from Phase 2b Trial of VT-1161 in Onychomycosis at the American Academy of Dermatology Annual Meeting
Mar 01, 2017: Viamet Announces RENOVATE Phase 2b Onychomycosis Results to be Presented at the American Academy of Dermatology 2017 Annual Meeting
Nov 08, 2016: Hallux Announces Start of Phase 2 Clinical Trial
Sep 28, 2016: Moberg Pharma Begins Patient Enrollment in North America and Europe in Two Phase 3 Studies of MOB-015 in Onychomycosis
Aug 10, 2016: Moberg Pharma Announces Approvals to Start Phase 3 Study For MOB-015 In U.S. And Canada
Jul 21, 2016: Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program
Jul 13, 2016: Viamet to Present Interim RENOVATE Results at the American Podiatric Medical Association 2016 Annual Meeting
Jul 05, 2016: Moberg Pharma announces submission of applications to start Phase 3 studies for MOB-015
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Dermala Inc, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix Inc, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Novan Inc, H1 2018
Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals Inc, H1 2018
Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2018
Onychomycosis (Tinea Unguium) - Dormant Projects, H1 2018 (Contd..1), H1 2018
Onychomycosis (Tinea Unguium) - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Onychomycosis (Tinea Unguium), H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

【レポートのキーワード】

爪真菌症(爪白癬)

★調査レポート[爪真菌症(爪白癬):治療薬開発パイプライン分析] (コード:GMDHC10088IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[爪真菌症(爪白癬):治療薬開発パイプライン分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆